BeOne Medicines (BEIGF) Capital Expenditures Growth (5y) (2020 - 2026)
Powered by 
Analysis
BeOne Medicines (BEIGF) Capital Expenditures Growth (5y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.95 Bn | 625.20 Bn | 17.26 Bn |
| 2 | AbbVie | 441.39 Bn | 434.82 Bn | 12.70 Bn |
| 3 | Merck | 366.72 Bn | 359.58 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.68 Bn | 258.99 Bn | 11.24 Bn |
| 5 | Pfizer | 159.20 Bn | 147.50 Bn | 10.94 Bn |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - |
| 8 | Incyte | 25.50 Bn | 20.96 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.54 Bn | 18.88 Bn | 683.80 Mn |
| 10 | BeOne Medicines | 2.48 Bn | -2.62 Bn | 1.53 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -8.28% |
| Mar 31, 2026 | 0.40% |
| Dec 31, 2025 | 1.58% |
| Sep 30, 2025 | 10.89% |
| Jun 30, 2025 | 7.73% |
| Mar 31, 2025 | 17.84% |
| Dec 31, 2024 | 43.00% |
| Sep 30, 2024 | 34.05% |
| Jun 30, 2024 | 59.02% |
| Mar 31, 2024 | 36.98% |
| Dec 31, 2023 | 46.51% |
| Sep 30, 2023 | 42.66% |
| Jun 30, 2023 | 62.83% |
| Mar 31, 2023 | 66.90% |
| Dec 31, 2022 | 45.00% |
| Sep 30, 2022 | 42.39% |
| Jun 30, 2022 | 53.68% |
| Mar 31, 2022 | 65.40% |
| Dec 31, 2021 | 70.15% |
| Sep 30, 2021 | 58.59% |